NASDAQ:VERA Vera Therapeutics Q1 2025 Earnings Results & Report $28.10 -0.94 (-3.24%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$28.11 +0.01 (+0.04%) As of 11/13/2026 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Vera Therapeutics missed analyst earnings expectations in its Q1 2025 results, released May 8, 2025. The company reported EPS of -$0.81 versus the -$0.75 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateMay 8, 2025TimeBefore Market OpensConference Call DateMay 6, 2025Conference Call8:00 AM ET Vera Therapeutics EPS ResultsActual EPS-$0.81Consensus EPS -$0.75Beat/MissMissed by -$0.06One Year Ago EPS-$0.56EPS Beat Rate3 of last 8 quartersVera Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Vera Therapeutics Q1 2025 Earnings FAQ Did Vera Therapeutics beat earnings estimates for Q1 2025? Vera Therapeutics (NASDAQ:VERA) reported earnings of -$0.81 per share for Q1 2025, missing the consensus estimate of -$0.75. The report was announced on Thursday, May 8, 2025. Vera Therapeutics Earnings HeadlinesJ.P. Morgan Remains a Buy on Vera Therapeutics (VERA)1 hour ago | theglobeandmail.comHC Wainwright Lifts Earnings Estimates for Vera TherapeuticsNovember 12 at 1:28 AM | americanbankingnews.comYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.November 14 at 1:00 AM | Profits Run (Ad)Vera Therapeutics (VERA) Receives a Hold from WedbushNovember 8, 2026 | theglobeandmail.comVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 6, 2026 | globenewswire.comVera Therapeutics (VERA) Stock Looks Above Fair Value After A 148% RunNovember 6, 2026 | finance.yahoo.comSee More Vera Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Vera Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vera Therapeutics and other key companies, straight to your email. Email Address About Vera TherapeuticsVera Therapeutics (NASDAQ:VERA) is a clinical-stage biotechnology company developing treatments for immune-mediated diseases. Headquartered in Brisbane, California, the company focuses on therapies intended to address underlying immune processes involved in conditions with significant unmet medical needs. Its lead investigational candidate, atacicept, is a fusion protein designed to inhibit BAFF and APRIL, proteins that support B-cell activity and antibody production. Vera is studying atacicept for IgA nephropathy and other autoimmune diseases. The candidate is investigational and has not been approved for commercial use. Vera was founded by physician and biotechnology executive Marshall Fordyce, who serves as the company’s chief executive officer. Its development work and clinical trials support its efforts to advance potential treatments for patients in the United States and other regions.View Vera Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/13Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCerebras Q3 Results: How Much More Proof Does Wall Street Need?YETI Beat on Earnings, But Its Sales Tell a Different StoryCostco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsLightPath Technologies' Record Backlog Highlights a Bigger Defense Opportunity Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
